The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation 1 . Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG) 2,3 . Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EGLN prolyl 4-hydroxylases that mark the hypoxia inducible factor (HIF) transcription factor for polyubiquitylation and proteasomal degradation 1 . Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumours but can suppress tumour growth in some other contexts. IDH1 and IDH2, which catalyse the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumours and leukaemias. The resulting mutants have the neomorphic ability to convert 2-OG to the (R)-enantiomer of 2-hydroxyglutarate ((R)-2HG) 2, 3 . Here we show that (R)-2HG, but not (S)-2HG, stimulates EGLN activity, leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes. These findings define an enantiomer-specific mechanism by which the (R)-2HG that accumulates in IDH mutant brain tumours promotes transformation and provide a justification for exploring EGLN inhibition as a potential treatment strategy.
To study the role of IDH mutations in brain tumours, we stably infected immortalized human astrocytes with retroviral vectors encoding haemagglutinin (HA)-tagged versions of wild-type IDH1, a tumourderived mutant (IDH1 R132H) 2,3 , or an IDH1 R132H variant in which three conserved aspartic acid residues within the IDH1 catalytic domain were replaced with asparagines (R132H/3DN) ( Fig. 1a and Supplementary Fig. 1 ). As expected, (R)-2HG levels, but not (S)-2HG levels, were markedly increased in the cells producing IDH1 R132H but not in cells producing the R132H/3DN variant ( Fig. 1b and Supplementary Fig. 2 ). In multiple independent experiments the IDH1 R132H cells acquired a proliferative advantage relative to cells producing the other versions of IDH1 beginning around passage 14, manifested as increased proliferation at confluence ( Fig. 1c ) and the ability to form macroscopic colonies in soft agar (Fig. 1d, e ).
Consistent with recent reports, we found that both (R)-2HG and (S)-2HG inhibit a number of 2-OG-dependent enzymes in vitro [4] [5] [6] , including the collagen prolyl 4-hydroxylases, the TET1 and TET2 methyl cytosine hydroxylases, the HIF asparaginyl hydroxylase FIH1 (also known as HIF1AN) and the JMJD2D (also known as KDM4D) histone demethylase, with (S)-2HG being a more potent inhibitor than (R)-2HG ( Supplementary Fig. 3 and data not shown). (S)-2HG was also a micromolar to low millimolar inhibitor of the three mammalian HIF prolyl 4-hydroxylases (EGLN1, EGLN2 and EGLN3) under standard assay conditions, which included 10 mM 2-OG (Supplementary Fig. 4 ). In contrast, (R)-2HG was not an effective EGLN inhibitor (half-maximum inhibitory concentration (IC 50 ) values . 5 mM; Supplementary Fig. 4 ). Moreover, we discovered unexpectedly that (R)-2HG, but not (S)-2HG, promoted EGLN1 and EGLN2 activity, and to a lesser extent EGLN3 activity, at tumour-relevant concentrations (low mM) in reactions that lacked exogenous 2-OG ( Fig. 2a , c, d and Supplementary Fig. 5a , b). This was specific because (R)-2HG did not promote collagen prolyl 4-hydroxylase activity ( Fig. 2b ) or JMJD2D histone demethylase activity (data not shown). Similar results were obtained with EGLN1 purified from either insect cells or Escherichia coli and with a heat-inactivated HIF polypeptide substrate ( Supplementary Fig. 6 ), making it unlikely that the ability of (R)-2HG to promote EGLN activity required a contaminating enzyme.
To determine how (R)-2HG might promote EGLN activity, we monitored the EGLN1 prolyl 4-hydroxylase reaction using liquid chromatography-mass spectrometry (LC-MS). 2-OG and succinate were detected when catalytically active EGLN1 was incubated with 5 mM (R)-2HG and a recombinant HIF-1a polypeptide, suggesting that EGLN1 can oxidize (R)-2HG to 2-OG, which is then decarboxylated to succinate during the hydroxylation reaction ( Fig. 2e and Supplementary Fig. 5c ). In support of this model, 13 C-labelled succinate was generated in EGLN hydroxylation assays that contained uniformly labelled 13 C-(R)-2HG ( Supplementary Fig. 5d ).
Consistent with the idea that (R)-2HG can substitute for 2-OG as a cosubstrate, the addition of increasing amounts of (R)-2HG to EGLN1 assays containing 10 mM 2-oxo-[1-14 C]glutarate progressively decreased the release of 14 CO 2 without decreasing the prolyl hydroxylation of HIF-1a, even at concentrations as high as 100 mM ( Supplementary  Fig. 7 ). Modelling of 2HG bound to the active site of EGLN1 predicts that binding of the (S)-enantiomer, but not the (R)-enantiomer, would prevent the subsequent recruitment of oxygen to the active site, perhaps accounting for the qualitatively different effects of the two enantiomers on EGLN activity ( Fig. 2f and Supplementary Fig. 5e ).
To investigate whether these findings were relevant in vivo we examined HIF levels in IDH1 mutant cells. In keeping with our biochemical results, HIF-1a and HIF-2a protein levels were reproducibly lower in mid-passage (passage 9-15) human astrocytes producing IDH1 R132H relative to control astrocytes ( Fig. 3a) , due at least partly to increased HIF-1a and HIF-2a hydroxylation and diminished protein stability ( Supplementary Figs 8 and 9 ), and were associated with lower levels of the HIF-responsive messenger RNAs encoding VEGF, GLUT1 and PDK1 ( Supplementary Fig. 10a ). Oxygen consumption and reactive oxygen species production, which can also affect HIF levels and the HIF response, were not measurably altered in the IDH1 mutant cells ( Supplementary Fig. 11 ). IDH1(R132H)expressing cells were relatively resistant to the 2-OG competitive antagonist dimethyloxalylglycine (DMOG), but not to the iron chelator deferoxamine (DFO) (Fig. 3b ), consistent with (R)-2HG acting as a 2-OG agonist in intact cells. In later passages (more than passage 20), HIF levels in IDH1(R132H)-expressing immortalized human astrocytes began to normalize despite persistent production of the exogenous IDH1 protein and (R)-2HG ( Supplementary Fig. 12 ), possibly due to adaptive HIF-responsive feedback loops such as those involving EGLN3 and microRNA miR-155 (refs 1, 7). These cells, however, retained the ability to form colonies in soft agar (data not shown) and remained addicted to EGLN activity (see later).
Similarly, the induction of HIF-1a and HIF-responsive mRNAs by hypoxia was diminished in two independent cell lines derived from two IDH1 R132H, 1p/19q-codeleted oligodendrogliomas compared to a control IDH1 wild-type, 1p/19q-codeleted oligodendroglioma line that had been generated in a similar fashion ( Fig. 3c and Supplementary Fig. 10b ). Although these three cell lines have similar growth kinetics in vitro (data not shown) they are not isogenic. We therefore also tested two HCT116 colorectal cancer cell sublines wherein the R132H mutation was introduced into the endogenous IDH1 locus by homologous recombination. These sublines also showed a diminished HIF response compared to wild-type cells unless EGLN was pharmacologically (DFO) or genetically (short hairpin (sh)RNA) inactivated ( Fig. 3d , e and Supplementary Fig. 13 ).
Finally, we asked whether IDH mutational status influenced HIF activity in primary patient astrocytoma samples using the TCGA expression data set 8 and a previously defined HIF-responsive gene expression signature 9 . The HIF signature was diminished in proneural tumours-which is the subtype most often associated with IDH mutations 8 -relative to other gene-expression-defined subtypes of brain cancer ( Supplementary Fig. 14a, b ) and, notably, was diminished in IDH mutant proneural tumours relative to wild-type proneural tumours ( Fig. 3f and Supplementary Fig. 14c ). Similar results were obtained with other previously published HIF gene sets and with a manually curated data set ( Supplementary Fig. 14a, d) .
Downregulating HIF-1a with three independent shRNAs promoted soft agar growth by immortalized human astrocytes after approximately 15 passages (Fig. 4a, b and Supplementary Fig. 15 ), as did overproduction of wild-type, but not catalytic-defective, EGLN1 (Fig. 4c, d and Supplementary Fig. 16 ). Conversely, downregulation of EGLN1 with multiple shRNAs inhibited the proliferation of late passage IDH1 R132H cells (Fig. 4e, f and Supplementary Fig. 17 ) unless HIF-1a was concurrently ablated (Fig. 4g , h and Supplementary Fig. 18 ).
Collectively, these data suggest that EGLN activation by (R)-2HG, and subsequent downregulation of HIF-1a, contributes to the pathogenesis of IDH mutant gliomas. Our data do not, however, exclude the possibility that (R)-2HG has additional targets, including TET2 and JmjC-containing histone demethylases, which contribute to its ability to transform cells 4-6 . Indeed, we found that downregulation of TET2 in human astrocytes also promotes soft agar growth (Supplementary EGLN2 EGLN3 Fig. 19 ). Nonetheless, our finding that (R)-2HG and (S)-2HG are qualitatively different with respect to EGLN might explain the apparent selection for (R)-2HG in adult tumours, despite the fact that (S)-2HG is a more potent inhibitor of most of the 2-OG-dependent enzymes tested so far. It should be noted, however, that (S)-2HG has been linked to neurological abnormalities and brain tumours in children and young adults with germline (S)-2-HG dehydrogenase mutations [10] [11] [12] . The pathogenesis of (R)-2HG-driven tumours linked to somatic IDH mutations in adults and (S)-2HG-driven tumours linked to inborn errors of metabolism conceivably differ, with the latter possibly reflecting the perturbation of one or more neurodevelopmental programs during embryogenesis.
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Nor are our data incompatible with the finding that HIF-1a protein levels are increased in IDH mutant tumours relative to normal brain 13 . Our data simply suggest that (R)-2HG quantitatively shifts the doseresponse linking HIF activation to hypoxia, leading to a blunted HIF response for a given level of hypoxia. In support of this idea, HIF elevation in IDH mutant tumours is usually confined to areas of necrosis and presumed severe hypoxia 14 .
Although HIF is typically viewed as an oncoprotein it can behave as a tumour suppressor in embryonic stem cells 15, 16 , leukaemic cells 17 and brain tumour cells 18, 19 . For example, HIF-1a has been shown to score as an oncoprotein when transformed murine astrocytes are grown subcutaneously but as a tumour suppressor when such cells are grown orthotopically 19 . This finding, together with our results, raises the possibility that pharmacological inhibition of EGLN activity (and the resulting increase in HIF activity) would impair the growth of IDH1 mutant tumours. A caveat, however, is that IDH mutant tumours tend to be relatively indolent 20 . It is possible that low levels of HIF-1a, although promoting some aspects of transformation, simultaneously suppress other hallmarks of cancer required for aggressive behaviour (such as angiogenesis).
The published 2-OG Michaelis constant (K m ) values for the EGLN family members are below the estimated intracellular 2-OG concentration 21, 22 , suggesting that 2-OG should not be limiting for EGLN activity and that EGLN activity would not be enhanced further by (R)-2HG. A caveat is that a considerable amount of intracellular 2-OG appears to be sequestered in mitochondria and might also be bound by other 2-OG-dependent enzymes 22 . Moreover, these 2-OG K m values were determined under idealized conditions with purified enzymes and substrates in the absence of endogenous inhibitors such as reactive oxygen species, nitric oxide and 2-OG competitive molecules such as succinate and fumarate 1 . Studies in model organisms suggest that many metabolic enzymes are saturated in vivo with a mixture of substrate and competitive inhibitors and thus are sensitive to changes in substrate concentrations that are far above their nominal K m values 23, 24 . We confirmed that succinate and fumarate increase the 2-OG requirement for the EGLN reaction and that their inhibitory activity, like that of DMOG ( Fig. 3b ) and its active derivative 2-oxalyl glycine, is blunted in the presence of (R)-2HG ( Supplementary Fig. 20) .
We have not yet formally proven that (R)-2HG is sufficient to downregulate HIF in intact cells. It is possible, for example, that additional metabolic changes in IDH mutant cells sensitize them to the HIF modulatory effects of (R)-2HG 25 . Another, potentially related, observation is that both downregulation of HIF and transformation by mutant IDH in immortalized human astrocytes, although highly reproducible, was only noted after multiple passages. HIF activates a number of genes, including genes that participate in feedback regulation of the HIF response and genes that modify chromatin structure 1 . It is possible that modulation of the HIF response over time, perhaps in conjunction with alterations in other enzymes affected by 2-HG, leads to epigenetic changes that ultimately are responsible for transformation. If so, it will be important to determine the degree to which such changes are reversible. Tubulin   Parental  Empty  IDH1  R132H  IDH1/3DN  R132H/3DN   a   TGFB3  PFKFB3  HK1  EDN1  CDKN1A  EGLN1  CP  BNIP3  BNIP3L  HMOX1  PGK1  HIG2  CA12  SERPINE1  FLT1  ADM  LOX  PFKFB4  CA9  TFRC  EGLN3  IGFBP3  EDN2  TGFA  TFR2  NDRG1 
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METHODS SUMMARY
NHAs immortalized with E6/E7/hTERT have been described elsewhere 26 and were subsequently infected with IDH retroviruses. IDH1 R132H HCT116 colorectal cancer cells were made by homologous recombination as previously described 27 .
Anaplastic oligodendroglioma cell lines were derived from resection material obtained at surgeries performed at the Brigham and Women's Hospital. Lentiviral shRNA vectors were from the Broad Institute. Immunoblots were performed with anti-HIF-1a monoclonal antibody (BD Transduction Laboratories), anti-HIF-2a polyclonal antibody (NB 100-122, Novus), anti-Flag monoclonal antibody (M2, Sigma-Aldrich), monoclonal anti-HA (HA-11, Covance Research Product), anti-EGLN1 monoclonal antibody (D31E11, Cell Signaling), anti-GLUT1 polyclonal antibody (NB300-666, Novus Biologicals), monoclonal antitubulin (B-512, Sigma-Aldrich) or anti-vinculin monoclonal antibody (V9131, Sigma-Aldrich). Metabolite levels were determined by LC-MS as previously described 2 . Enzyme activity assays were performed with affinity-purified human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 produced in insect cells using baculoviral vectors. (R)-2HG and (S)-2HG were from Sigma. (R)-2HG was free of contaminating 2-OG as determined by LC-MS under conditions that could detect 0.37 mM exogenous 2-OG in 5 mM (R)-2HG (data not shown). Human brain tumour mRNA expression data were obtained from The Cancer Genome Atlas and processed as described 8, 28 . Cell proliferation assays were performed using XTT assays (Cell Proliferation Kit II, Roche) according to the manufacturer's instructions or by direct counting of viable cells using an automated cell counter (Invitrogen). 
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Cell lines. The NHA cell line immortalized with E6/E7/hTERT has been described elsewhere 26 and was maintained in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in the presence of 10% CO 2 at 37 uC. Following retroviral infection, cells were maintained in the presence of hygromycin (100 mg ml 21 ). Introduction of the IDH1 R132H mutation into HCT116 colon cancer cell lines by homologous recombination was as previously described 27 . Briefly, targeting constructs were designed using the pSEPT rAAV shuttle vector 31 . Homology arms for the targeting vector were PCR amplified from HCT116 genomic DNA using Platinum Taq HiFi polymerase (Invitrogen). The R132H hotspot mutation was introduced in the targeting construct using the Quickchange II site-directed mutagenesis kit (Stratagene). An infectious rAAV stock harbouring the targeting sequence was generated and applied to parental HCT116 cells as previously described 32 , and clones were selected in 0.5 mg ml 21 geneticin (Invitrogen). Excision of the selectable element was achieved with an adenovirus encoding Cre recombinase (Vector Biolabs). Genomic DNA and total RNA were isolated from cells using QIAmp DNA Blood Kit and RNeasy kit (Qiagen). First strand cDNA was synthesized using iScript cDNA Synthesis Kit (BioRad). Successful homologous recombination and Cre-mediated excision were verified using PCR-based assays and by direct sequencing of genomic DNA and cDNA.
Anaplastic oligodendroglioma cell lines expressing wild-type IDH1 (BT260) or IDH1 R132H (BT237 and BT138) were derived from surgical resection material acquired from patients undergoing surgery at the Brigham and Women's Hospital on an Institutional Review Board approved protocol. Briefly, tumour resection samples were mechanically dissociated and tumospheres were established and propagated in Human NeuroCult NS-A Basal media (StemCell Technologies) supplemented with EGF, FGFb and heparin sulphate. All lines were obtained from the DF/BWCC Living Tissue Bank and confirmed to be derived from recurrent and progressive anaplastic oligodendrogliomas, World Health Organization grade III, at the time of cell-line isolation, and to have chromosome 1p/19q codeletion. The presence of IDH R132H mutation was confirmed by mutant specific antibody staining via immunohistochemistry and direct DNA sequencing. Vectors. Human IDH1 cDNAs (wild type and R132H) were subcloned as BamHI-EcoRI fragments into pBabe-HA-hygro. Aspartic acid residues 273, 275 and 279 were mutated to asparagines (N) by site-directed mutagenesis and confirmed by DNA sequencing. EGLN1, EGLN2 and EGLN3 cDNAs were subcloned into pLenti6-Flag expression vector after restriction with XbaI and EcoRI. pLenti6-Flag-EGLN1 P317R 33 was prepared by QuikChange Mutagenesis (Stratagene) using pLenti6-Flag EGLN1 as a template and the following oligonucleotides: 59-GTACGTCATGTTGATAATCGAAATGGAGATGGAAGATCTG-39 and 59-CACATGTTCCATCTCCATTTCGATTATCAACATGACGTAC-39. The entire EGLN1 coding region was sequenced to verify its authenticity. Lentiviral (pLKO.1) HIF-1a shRNA vectors (TRCN0000003810, target sequence: 59-GTGATGAAAGAATTACCGAAT-39; TRCN0000010819, target sequence: 59-TGCTCTTTGTGGTTGGATCTA-39; TRCN0000003809, target sequence: 59-CCAGTTATGATTGTGAAGTTA-39), EGLN1 (PHD2) shRNA vectors (TRCN0000001042, target sequence: 59-CTGTTATCTAGCTGAGTT CAT-39; TRCN0000001043, target sequence: 59-GACGACCTGATACGCCACT GT-39; TRCN00000010578, target sequence: 59-TGCACGACACCGGGAAGT TCA-39) and TET2 shRNA vectors (TRCN0000122172 (122), target sequence: 59-GCGTTTATCCAGAATTAGCAA-39; TRCN0000144344 (145), target sequence: 59-CCTTATAGTCAGACCATGAAA-39) were obtained from the Broad Institute TRC shRNA library. pLKO.1 shRNA with target sequence 59-GCAAG CTGACCCTGAAGTTCAT-39 was used as negative control shRNA. Immunoblot analysis. Cells extracts were prepared with 13 lysis buffer (50 mM Tris (pH 8.0), 120 mM NaCl, 0.5% NP-40) supplemented with a protease inhibitor cocktail (Complete, Roche Applied Science), resolved on 10% SDS-PAGE gels and transferred to nitrocellulose membranes (Bio-Rad). Membranes were blocked in TBS with 5% non-fat milk and probed with anti-HIF-1a monoclonal antibody (BD Transduction Laboratories), anti-HIF-2a polyclonal antibody (NB 100-122, Novus), anti-Flag monoclonal antibody (M2, Sigma-Aldrich), mouse monoclonal anti-HA (HA-11, Covance Research Product), anti-EGLN1(PHD2) monoclonal antibody (D31E11, Cell Signaling), anti-GLUT1 polyclonal antibody (NB300-666, Novus Biologicals), mouse monoclonal anti-tubulin (B-512, Sigma-Aldrich) or anti-vinculin monoclonal antibody (Sigma-Aldrich). Bound proteins were detected with horseradish-peroxidase-conjugated secondary antibodies (Pierce) and Immobilon western chemiluminescent horseradish peroxidase substrate (Millipore). LC-MS. Metabolite levels in samples were determined by negative mode electrospray LC-MS as previously described 2 . Briefly, metabolites were extracted from exponentially growing cells using 80% aqueous methanol (280 uC) and were profiled by LC-MS. (R)-2HG, 2-oxolutarate and succinate were quantified by LC-MS in negative mode using multiple reaction monitoring (MRM) on a Quattro micro triple quadruple mass spectrometer (Waters). Samples were diluted with equal amounts of 25% acetonitrile and 10 ml aliquots were analysed in triplicate. The HPLC column (Luna NH2, 3 mm, 2.0 3 100 mm, Phenomenex) was operated isocratically with 130 mM ammonium acetate pH 5.0 in 37% acetonitrile/ water. The MRM transitions were: 117 . 73, 117 . 93 (succinate), 145 . 57, 145 . 101 (2-OG) and 147 . 85, 147 . 129 ((R)-2HG), 0.2 s dwell time for all transitions. Calibration curves were set up with Quant Lynx, using standards dissolved in reaction buffer. Enzyme activity assays. (R)-2HG (H8378) and (S)-2HG (S765015) were from Sigma. (R)-2HG was free of contaminating 2-OG as determined by LC-MS under conditions that could detect 0.37 mM exogenous 2-OG in 5 mM (R)-2HG (data not shown). Human EGLN1, 2 and 3, collagen P4H-I and FIH, and murine Tet1 and Tet2 were produced in insect cells and purified as described earlier [34] [35] [36] [37] . The plasmids to generate the baculoviruses coding for Tet1 and 2 were a gift from Y. Zhang (University of North Carolina). IC 50 values for (R)-2HG and (S)-2HG were determined based on the hydroxylation-coupled stoichiometric release of 14 CO 2 from 2-oxo-[1-14 C]glutarate using synthetic peptides or double stranded oligonucleotides representing the natural targets of the studied enzymes as substrates. These were DLDLEMLAPYIPMDDDFQL (DLD19) for EGLN1, 2 and 3, (PPG) 10 for collagen P4H-I, DESGLPQLTSYDCEVNAPIQGSRNLLQGEELLRAL for FIH and 59-CTATACCTCCTCAACTT(mC)GATCACCGTCTCCGGCG-39 for Tet1 and 2. The K i values for (S)-2HG for EGLN1, 2 and 3 were determined by adding (S)-2HG in four constant concentrations while varying the concentration of 2-oxo-[1-14 C]glutarate.
To study whether (R)-2HG, which failed to efficiently inhibit EGLN activity, could promote EGLN activity by acting as a cofactor in the place of 2-OG, we determined the amount of 4-hydroxy[ 3 H]proline formed by a specific radiochemical procedure 38 Concentration of the purified substrate was measured by RotiQuant (Carl Roth GmbH) and it was used at K m concentrations for the distinct EGLN enzymes 40 . Modelling. EGLN1 active site structure (PDB accession 3HQR 29 ) with N-oxalylglycine (NOG, magneta), Mg 21 and a peptide substrate (light blue), was used to model (R)-2HG (green) and (S)-2HG (cyan) into the active site. Gene expression profiling and gene-set enrichment analysis. Expression data from human brain tumour samples were obtained from The Cancer Genome Atlas (http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) and processed as described 8, 28 . In short, 200 expression profiles from glioblastoma multiforme and two nonneoplastic brain samples were generated using three platforms (Agilent 244K, Affymetrix HT-HG-U133A, Affymetrix HuEx), preprocessed using gene centric probe sets and three expression values were integrated through factor analysis. After consensus clustering using 1,740 variably expressed genes, profiles with a negative silhouette metric were identified and removed from the data set, leaving expression profiles from 173 glioblastoma tumour samples. IDH1 mutation status was established for 116 out of the 173 samples.
Eleven gene sets representing response to induced hypoxia were reported in supplementary table 6 from ref. 41 . One gene set was from figure 4C in ref. 9 . A final set was assembled by one of us (W.G.K.) based on a literature review of genes upregulated by HIF in a wide variety of cell types (CA9, EGLN1, EGLN3, SLC2A1, BNIP3, ADM, VEGF, PDK1, LOX, PLOD1, CXCR4, P4HA1, ANKRD37). Single-sample gene-set enrichment analysis (GSEA) was applied as reported previously 8 . Briefly, genes were ranked by their expression values. The empirical cumulative distribution functions (ECDF) of both the genes in the signature as well as the remaining genes were calculated. An enrichment score was obtained by a sum of the difference between a weighted ECDF of the genes in the signature and the ECDF of the remaining genes. This calculation was repeated for all signatures and samples. Z-score transformation was applied to be able to make scores from different gene sets comparable. A positive score indicates gene set activation. A negative value does not indicate inactivation, but rather a lack of effect. Cell proliferation assays. Cells were plated in 96-well plates (,700 cells per well) with a media change every 3 days. The number of viable cells per well at each time point was measured using an XTT assay (Cell Proliferation Kit II, Roche) LETTER RESEARCH
